BetaEntity Annotation Prototype

Biomedical literature, made navigable

Follow the entities shaping the evidence.

Discover articles through diseases, drugs, treatments, interventions, clinical instruments, institutions and funders extracted from the BMJ open corpus.

Browse by entity family

An entity family is a category of extracted information. Choose one to browse its named entities and supporting articles.

View all families
29,499matching articles
244,054matching entity mentions
30popular entities listed
0%of mentions human-reviewed

Popular entities in these results

Choose an entity to see the articles in which it was identified.

Matching articles

29,499 articles · page 66 of 2459
BezafibratePrimary biliary cholangitisObeticholic acidUDCABZABarts Health NHS TrustUrsodeoxycholic acidcompensated cirrhosisOCAPBC

…cribed Ursodeoxycholic acid (UDCA), Obeticholic acid (OCA), and Bezafibrate (BZA), has shown biochemical benefit in patients with inadequat…

FruquintinibsintilimabCAPEOXoxaliplatincapecitabinechemotherapyimmunotherapyHenan Cancer Hospital

…cer, although there remains a need for improvement in efficacy. Fruquintinib, an oral and highly selective vascular endothelial growth facto…

INTESTIFIX 001-placeboINTESTIFIX 001sorafenibmelanomaHCCvancomycinatezolizumabvancomycin-placeboA/BCologne Microbiota Bank

…in, A/B+INTESTIFIX 001 in comparison to vancomycin-placebo, A/B+INTESTIFIX 001-placebo and safety of the therapeutic combination in advanced HCC. INTE…

bempedoic acidEzetimibePCSK9 inhibitorsacute myocardial infarctionatherosclerosisDyslipidaemiaAtorvastatinhigh-intensity statin therapyST-elevation myocardial infarction

… bempedoic acid, and 2% received a combination of Ezetimibe and bempedoic acid. No patients were initiated on PCSK9 inhibitors.Abstract 7-007 …